Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.5177
-0.0150-2.82%
Post-market: 0.52000.0023+0.44%19:59 EDT
Volume:5.75M
Turnover:3.01M
Market Cap:143.92M
PE:-1.04
High:0.5480
Open:0.5400
Low:0.5104
Close:0.5327
52wk High:2.55
52wk Low:0.5104
Shares:278.00M
Float Shares:245.00M
Volume Ratio:1.65
T/O Rate:2.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:4.60
PE(LYR):-2.01

Loading ...

Humacyte Files Form 3 Initial Beneficial Ownership Statement for Director Scott D. Coward

Reuters
·
Sep 29

Humacyte announces addition of Coward, Kuznik to board

TIPRANKS
·
Sep 28

Humacyte Adds Scott Coward to Board, Names Him to Audit Committee

Reuters
·
Sep 28

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

THOMSON REUTERS
·
Sep 28

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)

TIPRANKS
·
Sep 22

Humacyte Says FDA Authorizes Symvess Shelf Life Extension to 36 Months

Reuters
·
Sep 09

Humacyte - to File Supplemental Bla in Nov 2026 for Dialysis Access Indication

THOMSON REUTERS
·
Sep 09

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

THOMSON REUTERS
·
Sep 09

Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access

MT Newswires Live
·
Aug 24

Humacyte Says Phase 3 V012 Trial Shows ATEV Extends Catheter-Free Dialysis Time in Women

Reuters
·
Aug 24

Humacyte - Seeks to Add Dialysis Access as Second Approved Indication for Atev

THOMSON REUTERS
·
Aug 24

Humacyte - Supplemental Bla to be Supported by Three Phase 3 Studies of Atev

THOMSON REUTERS
·
Aug 24

Humacyte - to File Supplemental Bla with FDA for Atev in Dialysis Access in November 2026

THOMSON REUTERS
·
Aug 24

Humacyte Confirms Plans for Atev Supplemental Bla Filing for Dialysis Access Following FDA Discussions

THOMSON REUTERS
·
Aug 24

Humacyte Director Keith Anthony Jones Reports Purchase of 10,000 Common Shares Worth $6,930

Reuters
·
Aug 22

Humacyte Director Keith Anthony Jones Acquires 30,000 Shares Worth $17,820

Reuters
·
Aug 20

Humacyte Says Phase 3 V007 Trial Results Show ATEV Tops Fistula for Hemodialysis Access at One Year

Reuters
·
Aug 19

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

THOMSON REUTERS
·
Aug 19

Humacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints

TIPRANKS
·
Aug 14

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13